 All study participants will be treated with bevacizumab 15 mgkg plus docetaxel 75 mgm2 and cyclophosphamide 500 mgm2 every three weeks for a total of four treatments. Three weeks after the completion of this part of the treatment patients will start receiving doxorubicin 60 mgm2 every three weeks for a total of four treatments. All these drugs will be given as intravenous infusion on the first day of each three-week period. 